Melanoma (Skin)
359
20
31
232
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
44 trials with published results (12%)
Research Maturity
232 completed trials (65% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.2%
33 terminated out of 359 trials
87.5%
+1.0% vs benchmark
8%
27 trials in Phase 3/4
19%
44 of 232 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 232 completed trials
Clinical Trials (359)
Zr89 + PET Companion Trial
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
MoleGazer Development Feasibility Study
Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Rural Adult and Youth Sun Protection Study
New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
AI-based Medical Device Validation for Early Melanoma Detection
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma